MedTrace Logo

AS703569 Phase I in Patients With Solid Tumours

NCT00391521 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2014-01-30

No results posted yet for this study

Summary

This is a Phase I trial. Some specific protocol information is proprietary and is not publicly available at this time. Full information will be provided to trial participants.

Conditions

Interventions

DRUG

AS703569

Regimen 1: 3 mg/m2 /day given orally on Days 1 and 8 during a 21-day cycle

DRUG

AS703569

Regimen 2: 2 mg/m2/day given orally on Days 1, 2, and 3 of a 21-day cycle

DRUG

AS703569

Regimen 3: 10 mg/m2/day given orally on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle

Sponsors & Collaborators

Principal Investigators

  • Narmyn Rejeb, MD · Merck Serono S.A., Geneva

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00391521 on ClinicalTrials.gov